Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024
Engel B, Assis D, Bhat M, Clusmann J, Joostrenth, Gerussi A, Londoño M, Oo Y, Schregel I, Sebode M, Taubert R, Diseases I. Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024. JHEP Reports 2024, 101265. DOI: 10.1016/j.jhepr.2024.101265.Peer-Reviewed Original ResearchAutoimmune hepatitisInternational AIH GroupLiver transplant-free survivalAlternative first-lineCAR-T cellsRare chronic liver diseaseTransplant-free survivalDrug-induced autoimmunityChronic autoimmune responseEuropean Reference NetworkImmune-mediated diseasesChronic liver diseaseInitiative clinical trialsInflammatory bowel diseaseDecreased quality of lifeAIH patientsSalvage therapyRemission rateFirst-lineAIH groupT cellsStandard treatmentAutoimmune responseB cellsExpert centersAfrican American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis.
Yazdanfar M, Zepeda J, Dean R, Wu J, Levy C, Goldberg D, Lammert C, Prenner S, Reddy K, Pratt D, Forman L, Assis D, Lytvyak E, Montano-Loza A, Gordon S, Carey E, Ahn J, Schlansky B, Korzenik J, Karagozian R, Hameed B, Chandna S, Yu L, Bowlus C. African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis. Hepatology Communications 2024, 8 PMID: 38285883, PMCID: PMC10830082, DOI: 10.1097/hc9.0000000000000366.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisTransplant-free survivalInflammatory bowel diseaseHepatic decompensationNon-Hispanic whitesSclerosing cholangitisIncreased risk of clinical eventsNatural history of primary sclerosing cholangitisAssociated with transplant-free survivalHistory of primary sclerosing cholangitisAssociated with hepatic decompensationBowel diseaseProgression to hepatic decompensationRisk of clinical eventsDecompensation-free survivalMayo risk scoreAbnormal liver testsPerformance of prognostic modelsAfrican American raceRates of inflammatory bowel diseaseDeath/liver transplantationAA patientsLiver testsDiagnostic delayAA race